We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01433068
First Posted: September 13, 2011
Last Update Posted: February 20, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Nanobiotix
September 9, 2011
September 13, 2011
February 20, 2015
October 2011
May 2014   (Final data collection date for primary outcome measure)
  • Evaluation of the feasibility of the intratumor injection of NBTXR3 [ Time Frame: 6 months ]
    - To evaluate the feasibility of NBTXR3 given as intratumor implantation (by injection) and activated by external beam radiation in patients with soft tissue sarcoma of the extremity and trunk wall
  • Assessment of the safety profile and determination of early dose limiting toxicity [ Time Frame: 20 months ]
    - To assess the safety profile and determine the early dose limiting toxicity (DLT) of NBTXR3 intratumor implantation (by injection) and activated by external beam radiation
  • Evaluation of the feasibility of the intratumor injection of NBTXR3 [ Time Frame: 6 months ]
    - To evaluate the feasibility of NBTXR3 given as intratumor implantation (by injection) and activated by external beam radiation in patients with soft tissue sarcoma of the extremity
  • Assessment of the safety profile and determination of early dose limiting toxicity [ Time Frame: 20 months ]
    - To assess the safety profile and determine the early dose limiting toxicity (DLT) of NBTXR3 intratumor implantation (by injection) and activated by external beam radiation
Complete list of historical versions of study NCT01433068 on ClinicalTrials.gov Archive Site
  • Evaluation of the anti-tumor activity of NBTXR3 in terms of pathological Response (pR) [ Time Frame: 20 months ]
    - To evaluate the anti-tumor activity of NBTXR3 implanted within the tumor (by injection) at Day 1 and activated 24 hours later by external beam radiation therapy in terms of pathological Response (pR)
  • Evaluation of the Response Rate (RR) of NBTXR3 as per RECIST [ Time Frame: 20 months ]
    - To evaluate the Response Rate (RR) of NBTXR3 implanted within the tumor (by injection) at Day 1 and activated 24 hours later by external beam radiation therapy as per RECIST
  • Characterization of the body kinetic profile of NBTXR3 [ Time Frame: 20 months ]
    - To characterize the body kinetic profile of NBTXR3 implanted within the tumor (by injection) at Day 1 and Day 2 before its activation by radiation therapy
Same as current
Not Provided
Not Provided
 
NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity
An Open-Label, Single Arm, Feasibility And Safety Phase I Study With Nbtxr3 Intratumor Implantation (By Injection) And Activated By External Beam Radiation Therapy In Patients With Soft Tissue Sarcoma Of The Extremity And Trunk Wall

RATIONALE: Radiation therapy given before surgery of soft tissue sarcoma decreases the size of the tumor mass and the presence of malignant cells in its peripheral region. NBTXR3 and radiation therapy may kill more cancer cells and increase the tumor shrinkage rendering surgery more feasible or easier and achieve better local control of the tumor.

PURPOSE: This Phase I trial aims at evaluating the feasibility of the NBTXR3 injection in the tumor, safety and the adequate dose of NBTXR3 when given with radiation therapy.

Patients will receive a single intratumor injection of NBTXR3 on day 1 and will receive external beam radiotherapy starting on day 2 up to completion of 5 weeks, 5 days a week of treatment (50Gy, 2Gy/fraction). Then, all patients will undergo surgical resection of the tumor 5 weeks later and will be followed for wound healing and toxicity assessment. A visit of end of treatment will take place approximately 3-4 weeks after surgery. Patients will be followed for evaluation of their disease status and adverse events every 8 weeks until the end of study.
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Adult Soft Tissue Sarcoma
Device: NBTXR3
One intratumor implantation by injection
Experimental: NBTXR3
Intervention: Device: NBTXR3
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
22
February 2015
May 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age: 18 years and older
  • Soft tissue sarcoma of the extremity or trunk wall, or localized in the posterior region of the neck (i.e., coronal section passing through the posterior limit of the ear)
  • Locally advanced soft tissue sarcoma,candidate to radiotherapy

    • Primary tumor or,
    • Relapsed tumor, localized out of already irradiated area or,
    • Sarcomas secondary to previous irradiation exposure due to other primary cancer
  • WHO performance score 0 to 2
  • Adequate function of Bone marrow:
  • Adequate renal function
  • Adequate liver function
  • All female patients of childbearing potential must have a negative serum/urinary pregnancy test

Exclusion Criteria:

  • Written Informed Consent not obtained, signed and dated
  • Patients with the following histological type: Gastrointestinal Stromal Tumors (GIST), embryonal or alveolar rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma or chondrosarcoma, Kaposi's sarcoma, primitive neuroectodermal tumor or dermatofibrosarcoma protuberans
  • Soft tissue sarcoma of the trunk wall localized in the abdominal region, i.e. the region defined cranially by the xiphoid process of the sternum and the costal margins, and caudally by the line joining the anterior superior iliac spines, both limited by the perpendicular lines crossing both nipples
  • Angiosarcoma of the trunk wall because of its diffuse frontier
  • Metastatic disease (CT-scan verification) with survival expectation < 6 months
  • Concurrent treatment with any other anticancer therapy
  • Absence of histologically or cytologically proven cancer at the first diagnosis
  • Previous neoadjuvant chemotherapy treatment given as an upfront of the current treatment line
  • Previous radiation therapy in relapse site of the soft tissue sarcoma (no radiation re-challenge is permitted)
  • Moderate and severe liver dysfunction
  • Hemolytic anemia
  • Autoimmune disease
  • Complete initial work up earlier than 4 weeks prior to patient registration
  • Patients unable to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
  • Patients participating in another clinical investigation at the time of signature of the informed consent.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT01433068
NBTXR3-101
ID RCB : 2011-A00342-39 ( Other Identifier: Afssaps )
Yes
Not Provided
Not Provided
Nanobiotix
Nanobiotix
Not Provided
Principal Investigator: Sylvie BONVALOT, MD-PhD Head of Surgery Division
Principal Investigator: Guy KANTOR, MD-PhD Head of Radiotherapy Department
Nanobiotix
February 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP